42 results on '"Shide, Kotaro"'
Search Results
2. Whole-genome landscape of adult T-cell leukemia/lymphoma
3. Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma
4. Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas
5. CARD11 Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ
6. Dissecting Multicellular Ecosystems of HTLV-1 Infection and ATL By Multi-Omics Single Cell Analysis
7. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms
8. Depletion of Neoplastic CD11b Positive Cells in Jak2V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis
9. The Role of Calreticulin in Normal Hematopoiesis and Neoplastic Hematopoiesis of Myeloproliferative Neoplasms
10. Vitamin D receptor–mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis
11. Haploinsufficiency of CALR Confers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the Calr Mutation
12. TET2 Mutation Associated with Organ Infiltrations in ATLL
13. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
14. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms
15. Physiological Expression of Calr Mutant Increases Cell Growth and Cytokine Independency in Human Cell Lines Expressing Mpl, and Develops Essential Thrombocythemia in Mice
16. Mogamulizumab for ATLL in Clinical Practice
17. HMGA2 Orchestrates the Tumorgenesis of Myeloproliferative Neoplasms (MPN) in Corporation with JAK2V617F
18. Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma
19. Expression of HMGA2 Collaborates with JAK2V617F to Progress Myeloproliferative Neoplasms
20. Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma
21. Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma
22. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator
23. Therapies Targeting the MAPK Pathway Improve Bone Marrow (BM) Fibrosis Induced By JAK2V617F
24. Landscape of Genetic Alterations in Adult T-Cell Leukemia/Lymphoma
25. αSMA+ Macrophages Skewed From Hematopoietic Stem Cells By Vitamin D3 Initiate Myelofibrosis and Subsequent Osteosclerosis
26. Prognostic Factor, Including Relative Dose Intensity, For Adult T-Cell Leukemia/Lymphoma In Clinical Practice
27. Impact Of TET2 Deficiency On MPN Harboring JAK2V617F Mutation
28. Ezh2 Loss Accelerates JAK2V617F-Driven Primary Myelofibrosis
29. NS-018, a Selective JAK2V617F Inhibitor, Improves JAK2V617F-Induced Murine Myelofibrosis Without Decreasing The Erythrocyte Or Platelet Count
30. TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation
31. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm
32. NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant
33. Potentiated Activation of VLA-4 and VLA-5 Accelerates Proplatelet-Like Formation In Megakaryocytes.
34. Preferential Inhibition of An Activated Form of Janus Kinase 2 (JAK2) by a Novel JAK2 Inhibitor, NS-018
35. JAK2V617F Mutation Selectively Exerts the STAT3 Pathway for Enhancing a Neutrophil Activation Marker.
36. Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma.
37. Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.
38. Elevated Leukocyte Alkaline Phosphatase Scores Induced by Jak2 V617F Mutation
39. Expression of V617F JAK2 in Mice Leads to MPD Mimicking Human ET, Idiopahtic Myelofibrosis, and PV.
40. Tyrosine Kinase 2 (Tyk2) Interacts with and Phosphorylates Siva-1, and Auguments the Apoptotic Effect Induced by Siva-1.
41. Tyk2 Mutation Homologous to V617F Jak2 Is Not Found in Essential Thrombocythaemia, Although It Induces Constitutive Signaling and Growth Factor Independence.
42. Hmga2 collaborates with JAK2 V617F in the development of myeloproliferative neoplasms.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.